Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab effect on host-microbe interface in AD
NCT03389893Phase 4Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2018
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab + topical corticosteroids in atopic dermatitis (AD), sponsored by National Institute of Allergy and Infectious Diseases. Started Jul 2018; status: terminated.
02
Drugs
dupilumab + topical corticosteroids
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03389893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389893.